Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Jiang, Qian  [Clear All Filters]
2013
Wang J, Huang XJun, Jiang B, Jiang Q, Lu XJing, Xu LPing, Liu DHong, Chen H, Bao L, Lu J, et al. [Clinical characteristics and efficacy analysis for patients over 55 years of age with acute lymphoblastic leukemia]. Beijing Da Xue Xue Bao. 2013;45(6):938-44.
2015
He M, Fu Y, Yan Y, Xiao Q, Wu H, Yao W, Zhao H, Zhao L, Jiang Q, Yu Z, et al. The Hedgehog signaling pathway mediates drug response of MCF-7 mammosphere cells and breast cancer patients. Clin Sci (Lond). 2015.
2016
Li X, Jiang Q, Wang T, Liu J, Chen D. Comparison of the Antioxidant Effects of Quercitrin and Isoquercitrin: Understanding the Role of the 6″-OH Group. Molecules. 2016;21(9).
Zhao H, Tang H, Xiao Q, He M, Zhao L, Fu Y, Wu H, Yu Z, Jiang Q, Yan Y, et al. The Hedgehog signaling pathway is associated with poor prognosis in breast cancer patients with the CD44+/CD24‑ phenotype. Mol Med Rep. 2016.
Jiang Q, Gale RPeter. Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China. J Cancer Res Clin Oncol. 2016.
Jiang Q, Liu Z-C, Zhang S-X, Gale RPeter. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. J Cancer Res Clin Oncol. 2016.
2018
Qin Y-Z, Jiang Q, Jiang H, Lai Y-Y, Shi H-X, Chen W-M, Yu L, Huang X-J. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre. Br J Haematol. 2018.
Wang Y-Z, Hao L, Chang Y, Jiang Q, Jiang H, Zhang L-P, He L-L, Yuan X-Y, Qin Y-Z, Huang X-J, et al. A seven-color panel including CD34 and TdT could be applied in >97% patients with T cell lymphoblastic leukemia for minimal residual disease detection independent of the initial phenotype. Leuk Res. 2018;72:12-19.
2020
Zhang J-M, Xu Y, Gale RP, Wu L-X, Zhang J, Feng Y-H, Qin Y-Z, Jiang H, Jiang Q, Jiang B, et al. DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia. Br J Haematol. 2020.
Zhao X-Y, Jiang Q, Jiang H, Hu L-J, Zhao T, Yu X-X, Huang X-J. Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo. Eur J Immunol. 2020.
Wu Y-J, Hou M, Liu H-X, Peng J, Ma L-M, Yang L-H, Feng R, Liu H, Liu Y, Feng J, et al. A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data. Blood Adv. 2020;4(22):5846-5857.
Zhao P, Hou M, Liu Y, Liu H-X, Bin Huang R-, Yao H-X, Niu T, Peng J, Jiang M, Han Y-Q, et al. Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age. Platelets. 2020:1-9.
2021
Dou X, Zheng F, Zhang L, Jin J, Zhang Y, Liu B, Meng L, Zhu X, Lu Z, Jia Y, et al. Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study. Ann Hematol. 2021.
2022
Wang J, Liu W, Lu W, Luo X, Lin Y, Liu S, Qian J, Zhang C, Chen H, Li Y, et al. Sodium Tanshinone IIA Sulfonate Enhances the BMP9-BMPR2-Smad1/5/9 Signaling Pathway in Rat Pulmonary Microvascular Endothelial Cells and Human Embryonic Stem Cell-derived Endothelial Cells. Biochem Pharmacol. 2022:114986.
Cai X, Fu H, Zhao X, Lu J, Jiang Q, Chang Y, Huang X, Zhang X. Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study. Chin Med J (Engl). 2022;135(19):2344-2350.
2023
Li Y, Wang Y, Wang Z, Feng L, Gao L, Shi Y, Dang H, He Q, Qin Y, Jiang Q, et al. [Analysis of the characteristics of primary acute myeloid leukemia with 11q23/KMT2A rearrangements in ninety patients]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2023;40(12):1472-1477.
Sun Y-Q, Zhang X-H, Jiang Q, Jiang H, Chang Y-J, Wang Y, Xu L-P, Liu K-Y, Huang X-J. Comparison of haploidentical hematopoietic stem cell transplantation with chemotherapy in older adults with acute myeloid leukemia. Bone Marrow Transplant. 2023.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, et al. Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2023;16(1):13.
Zhu X, Jiang Q, Lu J, Sun Y, Zhao X, Yang S, Tang F, Yu W, Zhao T, Liu X, et al. COVID-19 infection in patients with haematological malignancies: A single-centre survey in the latest Omicron wave in China. Br J Haematol. 2023.
Cao L-M, Zhou Y-L, Gale RPeter, Qin Y-Z, Wu L-X, Zhao M-Y, Zhao X-S, Chen Y-H, Wang Y, Jiang H, et al. CSRP2 transcript levels after consolidation therapy increase prognostic prediction ability in B-cell acute lymphoblastic leukaemia. Biomol Biomed. 2023.
Tian J, Li Y, Bao X, Yang F, Tang X, Jiang Q, Yin Y, Yao K. Early weaning causes small intestinal atrophy by inhibiting the activity of intestinal stem cells: involvement of Wnt/β-catenin signaling. Stem Cell Res Ther. 2023;14(1):65.
Tang F, Zhao X, Ruan G, Jiang Q, Jiang H, Xu L, Wang Y, Zhang X, Liu K, Huang X. The effect of haploidentical hematopoietic stem cell transplantation on comutations based on next-generation sequencing in adult acute myeloid leukemia patients with the FLT3-ITD mutation. Hematol Oncol. 2023.
Ma L, Xu L-P, Wang Y, Zhang X-H, Chen H, Chen Y-H, Wang F-R, Han W, Sun Y-Q, Yan C-H, et al. Effects of isolated central nervous system involvement evaluated by multiparameter flow cytometry prior to allografting on outcomes of patients with acute lymphoblastic leukemia. Front Oncol. 2023;13:1166990.
Qi F, Zhang X, Gale RPeter, Liu B, Huang J, Huang X, Jiang Q. External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy. Leukemia. 2023.
Yang S, Zhang X, Gale RPeter, Du X, Chen C-Y, Weng J-Y, Huang J, Li F, Zeng Y, Xiao Z, et al. Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase. Am J Hematol. 2023.

Pages